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Abstract
The rapid advancement of next-generation sequencing (NGS) technology and the decrease in costs for whole-exome
sequencing (WES) and whole-genome sequening (WGS), has prompted its clinical application in several fields of
medicine. Currently, there are no specific guidelines for the use of NGS in the field of neonatal medicine and in the
diagnosis of genetic diseases in critically ill newborn infants. As a consequence, NGS may be underused with reduced
diagnostic success rate, or overused, with increased costs for the healthcare system. Most genetic diseases may be already
expressed during the neonatal age, but their identification may be complicated by nonspecific presentation, especially in
the setting of critical clinical conditions. The differential diagnosis process in the neonatal intensive care unit (NICU) may
be time-consuming, uncomfortable for the patient due to repeated sampling, and ineffective in reaching a molecular
diagnosis during NICU stay. Serial gene sequencing (Sanger sequencing) may be successful only for conditions for which
the clinical phenotype strongly suggests a diagnostic hypothesis and for genetically homogeneous diseases. Newborn
screenings with Guthrie cards, which vary from country to country, are designed to only test for a few dozen genetic
diseases out of the more than 6000 diseases for which a genetic characterization is available. The use of WES in selected
cases in the NICU may overcome these issues. We present an intersociety document that aims to define the best
indications for the use of WES in different clinical scenarios in the NICU. We propose that WES is used in the NICU for
critically ill newborn infants when an early diagnosis is desirable to guide the clinical management during NICU stay,
when a strong hypothesis cannot be formulated based on the clinical phenotype or the disease is genetically
heterogeneous, and when specific non-genetic laboratory tests are not available. The use of WES may reduce the time for
diagnosis in infants during NICU stay and may eventually result in cost-effectiveness.
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Background
Genetic disorders, including single-gene disorders, copy
number variations (CNVs) and chromosomal abnormal-
ities, are individually rare conditions, yet overall affecting
a substantial proportion of the general population [1, 2].
To date, a molecular characterization is available for 6011
of the more than 7000 identified genetic diseases [3].
The field of medical genetics has gained an increas-
ingly important role in recent years. The development of
novel techniques to investigate the genetic bases of hu-
man phenotypes and the concurrent reduction in the
costs for genomic analyses has boosted scientists and
clinicians to include the use of genomic techniques in
clinical practice [4].
The application of next-generation sequencing (NGS)
technology to interrogate the genomes of individuals,
families and cohorts in order to identify the molecular
defects responsible for diseases is maximally important
in the field of neonatal medicine. Indeed, despite the fact
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that genetic disorders may occur as late-onset conditions
(onset in adolescence or adulthood), many genetic con-
ditions are already clinically expressed during the first
28 days of life or shortly after [5].
Specific guidelines or recommendations for the use of
whole-exome sequencing (WES) and whole-genome se-
quencing (WGS) in the critically ill neonate are lacking.
The aim of the present intersociety policy statement is
to provide a rationale for the use of WES in the critically
ill newborn infant, to identify possible clinical scenarios,
and to set out the best indications for different tech-
niques in each scenario.
Epidemiology of genetic disorders in the neonatal
intensive care unit (NICU)
The actual incidence of genetic diseases in the NICU is
unknown because many potentially genetic conditions
are often not appropriately investigated during hospital
stay, or genetic tests are performed later on in life.
Moreover, some genetic conditions may be silent or only
partially expressed and not easily recognizable during
the neonatal age.
A major group of diseases occurring in neonatal units
with potential genetic origin are congenital anomalies, also
referred to as birth defects or congenital malformations.
Birth defects occur in 2–3% of live births [6–9], congenital
heart disease in 1% [10], and inborn errors of metabolism
in 0.5% [11]. It has been estimated that birth defects,
neuromuscular disorders, neurodevelopmental delay and
intellectual disability overall affect 10% of all live births.
Approximately 20% of infant mortality in the US is esti-
mated to occur due to birth defects and/or chromosomal
abnormalities [12]. Despite the reduction by 50% of the
overall neonatal mortality thanks to the improvement in
neonatal intensive care techniques, mortality due to birth
defects has remained stable across the past 30 years. Both
genetic and non-genetic etiologies have been identified, in-
cluding prenatal infections, parental exposure to teratogens,
events occurring during pregnancy and, among genetic fac-
tors, chromosomal aneuploidy, copy number variations and
monogenic conditions.
Monogenic disorders, also referred to as single-gene
disorders, are diseases due to genetic defects disrupting
the function of one single gene. The resulting phenotype
may be highly variable in terms of organ and tissue in-
volvement, clinical severity and age at onset. Currently,
4969 monogenic disorders have been described, caused
by genetic variations in 3378 genes [3]. The actual inci-
dence of monogenic disorders underlying clinical disease
in the NICU is unknown.
Importance of the etiologic diagnosis in the NICU
The molecular characterization of a disease phenotype
in the NICU may have fundamental practical
implications. First, it can provide a diagnostic response
to families. Second, if specific treatments are available
for the identified disease, it provides the rationale for the
use of targeted therapies and withdrawal of empirical,
ineffective or potentially harmful treatments, thus result-
ing in life-saving changes in the clinical management of
the patient. Further, parents can be provided with de-
tailed prognostic counseling useful to predict potential
late-onset complications, to design preventive strategies
and rehabilitation, and to early acces specific therapeutic
protocols or programs for infants with special needs.
Moreover, the molecular characterization of the patient’s
disease may help parents to better plan their future re-
productive choices based on the risk of familial recur-
rence, and to early identify the disease genes in other
current or future family members [5]. Finally, the etio-
logic definition of the clinical phenotype may be useful,
in critical care settings for diseases with unfavourable
prognosis, to discuss with the family the most appropri-
ate end-of-life decisions. Altogether, targeted interven-
tions in the critical newborn based on the molecular
etiology of the disease may result in improved clinical
management and in overall reduced mortality and mor-
bidity in the NICU and in the involved families.
Technologies for clinical genetic testing in the NICU
A comprehensive description of all available techniques
for genetic testing is beyond the scope of the present re-
view. Here we briefly list the techniques that are more
commonly used for the diagnosis of genetic disorders in
clinical settings, and further focus on the clinical appli-
cation of NGS methodologies.
The identification of neonatal diseases through the
non-genetic testing with the Guthrie cards (newborn
screening) is highly sensitive and rapid, can efficiently
detect actionable neonatal disorders, and is an invaluable
prevention tool, but it is designed to test only a limited
number of genetic diseases [13–16].
Microarray techniques, including array-Comparative
Genomic Hybridization (array-CGH) and single nucleotide
polymorphism-array (SNP-array), are the techniques of
choice for the identification of chromosomal aneuploides
and CNVs [17]. The standard karyotype is necessary for the
diagnosis of balanced chromosomal abnormalities (e.g. bal-
anced translocations) that are usually not detected with mi-
croarrays. Because cranio-facial defects, multiple birth
defects, neurodevelopmental delay, intellectual disability
and pervasive developmental disorders are often caused by
chromosomal abnormalities or CNVs, array-CGH or SNP-
array are the first-line technologies for the characterization
of these disorders [18].
Serial gene sequencing (e.g. Sanger sequencing) can be
successfully used, in the setting of suspected monogenic
conditions, to study a limited number of genetic defects.
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However, serial gene sequencing is often too slow to pro-
vide useful information in the short term during NICU
stay, especially for genetically heterogeneous diseases (de-
fects in several genes underlying the same phenotype),
and a diagnosis is often returned after patient’s discharge
or death. Furthermore, it requires a strong diagnostic hy-
pothesis and prior knowledge of the disease-causing
genes. As a consequence, the clinical management of the
newborn infant in the NICU seldom relies on genetic in-
formation obtained through serial gene sequencing.
The NGS technology is based on the so-called massive
parallel sequencing and can be used to sequence the whole
genome of an individual (i.e., WGS), or specific target re-
gions, in few days. The most widely used application of
NGS is WES [19], consisting of the simultaneous sequen-
cing of all the coding regions of the genome (the exons).
NGS is designed to identify single nucleotide variations
(SNVs) and small insertions/deletions (InDels), and is pri-
marily used for the diagnosis of monogenic disorders.
WES and WGS have also been applied to the analysis
of CNVs [20–22], but array-CGH is currently the first-
line technology to use when diseases caused by CNVs
are suspected.
Clinical applications of NGS
Since the first publication in 2009 on a genetic diag-
nosis using the NGS technology [23], a series of pub-
lications on both pediatric and adult patients have
unquestionably demonstrated the clinical utility of
WES/WGS [24]. In adult and pediatric patients, NGS,
and specifically WES, has been demonstrated to be
able to change the decision-making processes at the
bedside, to guide the long-term clinical management,
and to affect the prognosis, when actionable condi-
tions are identified [25].
Similarly, NGS has been successfully applied to obtain
the molecular explanation of complex fetal and neonatal
conditions with nonspecific or incomplete syndromic
presentations or for genetically heterogeneous condi-
tions. In some cases, the molecular characterization of
the condition allowed to modify the clinical manage-
ment and the therapeutic decisions [26–28].
For birth defects, the diagnostic success rate of WES is
20–25% when the analysis is restricted to known
disease-genes, and may be as high as 45% for specific
conditions as, for instance, neurodevelopmental disor-
ders [2]. As a comparison, the diagnostic success rate is
~25% for Sanger sequencing and ~20% for microarray
techniques and standard karyotype [29].
Specific study designs and diagnostic strategies may
increase the success rate of NGS.
Family- or trio-based analyses are designed to test spe-
cific and the most likely genetic hypotheses (autosomal
dominant, autosomal recessive, X-linked) or to restrict
the analysis to variants shared by affected and absent in
unaffected members of the kindred [30].
The success rate of NGS increases when the patient’s
history and description, including laboratory and imaging
studies, are reported in detail and with high accuracy.
WES associated with the so-called deep clinical phenotyp-
ing achieved a success rate of 68% for the molecular
characterization of inborn errors of metabolism, with ac-
tionable diagnoses obtained in 44% of all cases [25].
Reaching a genetic diagnosis through WES or WGS is
complex and laborious. The huge amount of data generated
during a NGS experiment must be handled by expert bioin-
formaticians. Several potentially pathogenic variants of un-
known significance are identified during a single WES/
WGS experiment and data interpretation is a critical step.
The identification of the causative variant responsible for
the phenotype under study, when achieved, is based on hard
filtering or variant prioritization according to several criteria
[31]. These include allele frequency of the identified genetic
variant in public databases (e.g., gnomAD, 1 kg) [32, 33],
predicted loss-of-function or pathogenicity of the variant,
the most likely genetic model (autosomal dominant, auto-
somal recessive, X-linked, de novo), the conservation of the
protein domain, gene function, and previous publications
reporting proof of causality between the same variant or
other variants in the same gene and the patient’s phenotype.
Data interpretation has greater success when per-
formed as a multidisciplinary process. The first funda-
mental step is the accurate phenotyping of the patient
and the annotation of all the relevant clinical, laboratory
and instrumental signs by the neonatologist or by the
clinical geneticist, which allows a more effective variant
prioritization based on gene function or on previous as-
sociations between variants and similar phenotypes in
public databases (e.g. ClinVar) [34].
Use of NGS for the molecular diagnosis in the newborn
infant
Difficulties in the molecular diagnosis of neonatal condi-
tions include:
– Phenotypic variability (incomplete penetrance,
variable expressivity);
– Genetic heterogeneity, even for highly homogenous
and clinically recognizable phenotypes, complicating
the diagnostic workup;
– Poor index of suspicion for a genetic condition in
the neonatal age because i) the disease phenotype is
not fully expressed early in life, or ii) clinical signs
are subtle and highly aspecific or masked, especially
in the setting of critical conditions.
These infants usually undergo extensive testing with
repeated blood sampling and imaging studies, that are
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often unable to provide a molecular characterization or
a diagnostic response.
NGS technology allows the simultaneous sequencing
of more than 20,000 genes (for WES) or a panel of
preselected genes, and can be efficiently used in clin-
ical settings to at least partially overcome these issues.
For this reason, beyond applications in research pro-
jects, an increasing number of clinical laboratories is
using NGS-based genetic testing for the diagnosis of
suspected genetic conditions.
Because a substantial proportion of known genetic
conditions may have clinical impact during the first
28 days of life, the NICU is among the medical environ-
ments with highest potential for successful application
of NGS technology.
For neonatal medicine, NGS technology may have a
critical role for the diagnosis of:
i) Suspected genetic conditions which are
phenotypically nonspecific and not consistent with
any known syndrome;
ii) A condition consistent with a genetic disease known
to be genetically heterogenous, for which non-
genetic laboratory testing is not available, and for
which classical Sanger sequencing would be costly
and would require a long diagnostic time;
iii)Suspected genetic conditions in the critically ill
neonate for which a rapid diagnosis is relevant to
the clinical decision-making process in the NICU.
Moreover, a timely diagnosis during hospital stay
may result in a shorter time for the differential diag-
nosis, shorter NICU stay, use of specific treatments
and avoidance of nonspecific and ineffective drugs
and, ultimately, in an overall reduction of the health-
care costs for the patient. Therefore, with the pro-
gressive reduction in the costs for NGS, a timely
diagnosis with NGS in selected NICU patients may
eventually result in cost-effectiveness [5, 27].
Current advantages of WES over WGS
WES is designed to only identify genetic variations in
the exonic regions and the flanking intronic regions (1–
1.5% of the whole genome), while most genomic non-
coding regions are not covered by the analysis. Never-
theless, WES is the most widespread application of NGS
to identify rare genetic variations underlying Mendelian
disorders because of its cost-effectiveness. Indeed, ap-
proximately 85% of the identified human disease-causing
variants are located in the exonic regions [35, 36].
Better coverage and slightly higher sensitivity in de-
tecting genetic variants, especially in splice-site and in-
tronic regions flanking the exons, may be obtained with
WGS [37]. However, despite a reduction in the costs
over the past few years, WGS is still less cost-effective
than WES, and requires a longer time for analysis and
higher computational costs [38]. In the future, a further
reduction in the costs for sequencing and the rapid evo-
lution of the technology together with the development
of novel protocols for rapid diagnostic WGS may de-
crease the computational time and resources needed for
WGS and tip the balance towards the use of WGS as
first-line test for clinical use [5, 27].
Policy statement on the use of WES in the NICU
The above considerations represent the rationale for de-
fining the diagnostic indications to the use of WES in
the critically ill newborn infant.
The boards of the four involved scientific societies desig-
nated one or two members from each society to draft to-
gether the first version of the policy statement. The draft
circulated among all the members of the boards of each
involved scientific society. Each board member edited the
draft and expressed his/her concerns. A final version in
Italian language, addressing all the concerns and accepting
the proposed modifications, was eventually drafted, ap-
proved by the members of the boards, and published on
the websites of the four involved scientific societies.
As a general indication, the current intersociety policy
statement proposes that WES should be performed in
critically ill newborn infants if a diagnostic hypothesis is
not achievable based on the sole clinical phenotype, and
for suspected conditions with a highly heterogenous mo-
lecular pathogenesis (Fig. 1).
Specifically, a genetic diagnosis should always be
seeked in the following situations:
i) Life-threatening, critical conditions (e.g.
cardiopulmonary failure, multiorgan failure) lacking
medical explanation (high risk of short-term
mortality);
ii) Severe organ disease of unknown pathogenesis,
especially in case of poor responsiveness to standard
treatment;
iii)Severe congenital malformations that are not
consistent with any known syndrome;
iv) Severe unexplained neurological signs;
v) Metabolic failure of unknown origin;
vi) Severe, nonspecific and undifferentiated conditions
at birth;
vii) Other unexplained acute conditions;
The above listed conditions can occur in three pos-
sible scenarios:
Scenario 1. A non-genetic etiology is the most likely ex-
planation for the clinical conditions based on the pre- and
peri-natal history, and/or has been confirmed with labora-
tory and imaging studies. The diagnostic workup for the
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specific disease should be followed. The patient should be
treated according to the specific therapeutic protocol.
Scenario 2. The phenotype is highly consistent with a
known genetic condition:
- If the disease is known to be genetically homoge-
neous (few genes are known to underlie the disease), if
serial gene sequencing can provide results in a short
time, and/or if non-genetic, rapid laboratory tests (e.g.
biochemical) are readily available, the patient should be
tested for defects in selected genes or undergo specific
laboratory testing;
- If the disease is genetically heterogeneous, if rapid
non-genetic laboratory tests are not available, and a gen-
etic laboratory with experience in the disease cannot
provide a diagnostic response with serial gene sequen-
cing in a short time, the patient should undergo array-
based genetic testing for CNVs, followed by WES in case
of negative results.
Scenario 3. The phenotype, regardless of the complex-
ity of the clinical picture, is not consistent with any
known genetic condition, and any possible known, non-
genetic condition consistent with the phenotype has
been excluded. In such a scenario, the patient should
undergo array-based genetic testing for CNVs followed
by WES in case of negative results.
The presence of familial recurrence or consanguineous
parents in the patient’s history, a severe form of a com-
monly mild phenotype (the so-called “extreme phenotype”),
and the slow or absent reponse to drugs that are usually ef-
fective, increase the likelihood of (although their absence
does not exclude) a genetic condition.
Genetic counseling should always be requested prior
to genetic analyses to obtain guidance on the opportun-
ity to perform genetic testing, to obtain information on
the most appropriate genetic diagnostic workup, or be-
fore excluding the utility of any genetic analyses in the
specific clinical case.
Genetic counseling with the families should also be
planned after the results of the genetic tests are available to
provide prognostic information to the parents and design
the most appropriate health program for the patient and
the family.
The importance of establishing an early genetic diagnosis
in these conditions cannot be overstated. A genetic diagno-
sis has critical practical implications, including avoidance of
unnecessary and repeated blood sampling and invasive
diagnostic studies, administration of patient-targeted treat-
ments, establishment of disease-specific, protocol-based
follow-up programs, prevention of potential long-term
complications and sequelae often associated with a diagnos-
tic delay of a genetic disease, and, in case of unfavourable
prognosis, discussion with the family about the most appro-
priate end-of-life decisions.
If a fulminant and fatal form of a disease does not allow
the reaching of a diagnostic response before patient’s
death, biological samples from the patient should always
Fig. 1 Diagnostic algorithm for genetic testing in the critically ill newborn infant
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be stored for subsequent diagnosis, which may be useful
to the family to predict the risk of familial recurrence.
Ethical considerations
General ethical issues related to clinical use of WES in-
clude: i) potential identification of genetic defects that are
unrelated to the clinical phenotype for which WES was in-
dicated, sometimes associated with a late-onset phenotype
or a carrier status; ii) potential identification of variants of
unknown significance; iii) privacy and data security issues,
particularly sensitive for individuals in the pediatric age.
The decision on which secondary data should be commu-
nicated is a matter of debate [39]. In some countries there is
agreement on which incidental findings can be communi-
cated [39]. The American College of Medical Genetics and
Genomics published and recently updated a minimum list
of genes to be reported as incidental or secondary findings,
with the aim of preventing or significantly reducing morbid-
ity and mortality for selected highly penetrant genetic disor-
ders [40]. Specifically for newborn infants, the “BabySeq
project” recently published a curated gene list for reporting
results of newborn genomic sequencing [41].
The list of genes to report is linked to the current know-
ledge, and the rapid discovery of novel variants and novel
disease-genes will require periodic update of the lists of
genetic variations and genes to be communicated.
The current policy of the Italian Society of Human
Genetics (Società Italiana di Genetica Umana, SIGU) is
to rely on the patient’s or parent’s decision, after detailed
information has been provided and informed consent
has been signed [42]. A possible solution is to decide
prior to the analysis which data should be communi-
cated. In the most restrictive option, only variants re-
lated to the disease for which WES was indicated that
are actionable for the patient or other family members
will be communicated while variants of unknown origin
or variants predisposing to late-onset diseases or associ-
ated with carrier status, that do not modify the short
term clinical decisions, will not be communicated.
The Institutional Review Board of the institution
should always be involved when specific situations do
not allow an agreement on a specific communication
policy with the parents.
Regarding privacy and security issues, specific invest-
ments from political and healthcare institutions and or-
ganizations are required to guarantee safe long-term
storage of the genomic data after appropriate de-linking
of the patient’s name with the stored data.
Potential future applications of NGS in neonatal medicine
Newborn screening
The use of NGS for newborn screening is object of discus-
sion [43–45]. Before NGS can be integrated in the universal
newborn screening, however, several issues should be
solved, including ethical (e.g. communication of results to
families, ownership of the data), financial (costs for sequen-
cing and data storage), security (appropriate encryption/de-
cryption methods) and technical issues (time for
sequencing and bioinformatics analysis, interpretation of
the results, optimization of the starting material for DNA
extraction) [46].
Use of rapid WGS for genetic diagnosis in the NICU
The use of rapid WGS for targeted genetic diagnosis in the
NICU was first suggested by a research group at Children’s
Mercy Hospital (Kansas City, MO, USA), and WGS alone
or in combination with RNA-sequencing is currently used
by other groups [5, 27]. By reducing the sequencing time
(rapid mode sequencing) and automatizing the bioinformat-
ics pipeline, researchers have been able to provide a genetic
diagnosis in NICU, from blood sampling to results, in 26 h,
with a success rate of 57% when applied to a carefully se-
lected population of patients [38]. Despite being promising
in clinical trials, similar results would not be easily obtained
in daily clinical practice. Indeed, the widespread adoption of
rapid WGS or WGS + RNA-sequencing is nowadays costly
and requires highly specific expertise. WES currently re-
mains the methodology of choice in laboratories for the
diagnosis of monogenic conditions in the NICU.
Conclusions
Specific recommendation or guidelines for the use of
NGS technology in the neonatal age are lacking. Most
genetic diseases are clinically relevant during the neo-
natal age. The diagnosis of genetic diseases with serial
gene sequencing or with non-genetic testing may be
time-consuming, uncomfortable for the patient, and
often ineffective in reaching a molecular diagnosis
during NICU stay. The present intersociety document
proposes to use WES for genetic diagnosis in critic-
ally ill newborn infants when a strong hypothesis on
the likely genetic diseases cannot be reached based on
the phenotype, a rapid diagnosis may lead to changes
in clinical management during hospital stay, or when
the suspected genetic condition is genetically hetero-
geneous. The use of WES may reduce the time for
diagnosis in infants during NICU stay while being
cost-effective.
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